Replies to post #809095 on NorthWest Biotherapeutics Inc (NWBO)

[brooktrail1933]

Ex the erudite (mis)speller:

"benjimens"

BENJAMINS

[flipper44]

Everyone knows Merck UCLA and DCVax-l are testing the waters with Keytruda and DCVax-l (lab version), except you. Everyone knows DCVax-l has a combo patent in dozens of countries which includes but is not limited to all European countries. It goes out to about 2035/2036, and might be expandable to other indications.

Everyone knows if Merck wants to do a large II/III combo trial using Keytruda and commercially made DCVax-l (when/if) available, the FDA would not stop them.

Do you really need to stay on one freaking side of the fence every second?

Tool on…

[dstock07734]

Do you really not know how keytruda works? Massive number of t-cells have to show up in tumor microenviroment in the first place. Then keytruda can unmask t-cells by inhibiting pd1 protein on the surface of t-cells so that they can see cancer cells better.

Repeat after me: There is only treatment on this planet that can trigger massive and sustainable t-cell infiltration into tumor site both hot and cold. That treatment is called DCVax of which $NWBO solely own the technology. Is this simple enough for you to digest?

[Doc logic]

exwannabe,

Funny that you mention Optune because L seemed to work well with Optune in the Phase 3 but this is based on pretty limited data. Still nothing to shrug at if I am a researcher or patient in need of answers right? For investors, though, if something even better is coming along that works with both but needed to overcome manufacturing hurdles to gain a wide spread market opportunity in multiple indications and is headed in the right direction, maybe investors might want to be with what has a wider application base that currently is not factored in to its company stock price.
Now let’s ask why all those trials you mentioned don’t include a base product that by nature is tissue/indication agnostic. NWBO shouldn’t need to prove a given but still only needs to demonstrate this by using acceptable current examples like Dr. Kalinski’s VEGF(?) pre targeted DCs which NWBO has full rights to. Go phish!; ). Best wishes.